We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hutchmed (china) Limited | LSE:HCM | London | Ordinary Share | KYG4672N1198 | ORD USD0.10 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 296.00 | 293.00 | 296.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 838M | 100.78M | - | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMHCM
RNS Number : 4126O
Hutchison China Meditech Limited
18 August 2017
Directors' Share Dealing
London: Friday, August 18, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that:-
(a) Mr Simon To, Executive Director and Chairman, through Wencheng Capital Limited ("WCL"), a person closely associated ("PCA") with Mr To, purchased a total of 4,900 American Depositary Shares of the Company ("ADSs", each representing one half of one ordinary share of US$1.00 each in the capital of Chi-Med) on August 15, 2017 at a price of US$24.50 per ADS. WCL is controlled by the trustee of Wencheng Trust ("WT") which has been established for the benefit of Mr To's family member, of which Mr To is the settlor; and
(b) Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 5,336 ADSs at an average price of US$24.92 per ADS on August 16 and 17, 2017.
Following the above purchases, (i) Mr To is interested in 118,489 ADSs (in Dynamic Drive Trust ("DDT") and WT of which his family members are the beneficiaries) and 180,000 Ordinary Shares (including the holding of 78,000 Ordinary Shares in DDT of which his family members are the beneficiaries), representing in aggregate approximately 0.39% of the current issued share capital of Chi-Med; and (ii) Ms Shih is interested in 96,000 ADSs and 70,000 Ordinary Shares, representing approximately 0.19% of the current issued share capital of Chi-Med.
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
(a) Wencheng Capital Limited
Hot Features
Premium
1 Details of the person discharging managerial responsibilities/person closely associated
----- ---------------------------------------------------------------------------------------------------------------
a) Name Wencheng Capital Limited
----- ------------------------------------ -------------------------------------------------------------------------
2 Reason for the notification
----- ---------------------------------------------------------------------------------------------------------------
a) Position/status Person closely associated with Mr Simon To, Executive Director and
Chairman. Wencheng Capital
Limited is controlled by the trustee of Wencheng Trust which has been
established for the
benefit of Mr To's family members, of which Mr To is the settlor.
----- ------------------------------------ -------------------------------------------------------------------------
b) Initial notification/Amendment Initial notification
----- ------------------------------------ -------------------------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----- ---------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
----- ------------------------------------ -------------------------------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
----- ------------------------------------ -------------------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----- ---------------------------------------------------------------------------------------------------------------
a) Description of the financial ADS each representing one half of one Ordinary Share of US$1.00
instrument, type of instrument ADS ISIN: US44842L1035
Identification code
----- ------------------------------------ -------------------------------------------------------------------------
b) Nature of the transaction Acquisition of 4,900 ADSs in the name of Wencheng Capital Limited which
holds the ADSs for
a family trust (Wencheng Trust) of which Mr To is the settlor on August
15, 2017 at a price
of US$24.50 per ADS.
----- ------------------------------------ -------------------------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
----- ------------------------------------ ------------------------------------ -----------------------------------
US$24.50 4,900
------------------------------------------------------------------------------- -----------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
----- ------------------------------------ -------------------------------------------------------------------------
e) Date of the transaction 2017-08-15
----- ------------------------------------ -------------------------------------------------------------------------
f) Place of the transaction Nasdaq Stock Market
----- ------------------------------------ -------------------------------------------------------------------------
(b) Ms Edith Shih
1 Details of the person discharging managerial responsibilities/person closely associated
----- ---------------------------------------------------------------------------------------------------------------
a) Name Ms Edith Shih
----- ------------------------------------ -------------------------------------------------------------------------
2 Reason for the notification
----- ---------------------------------------------------------------------------------------------------------------
a) Position/status Non-executive Director and Company Secretary
----- ------------------------------------ -------------------------------------------------------------------------
b) Initial notification/Amendment Initial notification
----- ------------------------------------ -------------------------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----- ---------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
----- ------------------------------------ -------------------------------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
----- ------------------------------------ -------------------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----- ---------------------------------------------------------------------------------------------------------------
a) Description of the financial ADS each representing one half of one Ordinary Share of US$1.00
instrument, type of instrument ADS ISIN: US44842L1035
Identification code
----- ------------------------------------ -------------------------------------------------------------------------
b) Nature of the transaction Acquisition of 5,336 ADSs on August 16 and 17, 2017 at an average price
of US$24.92 per ADS.
----- ------------------------------------ -------------------------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
----- ------------------------------------ ------------------------------------ -----------------------------------
US$24.73 1,000
------------------------------------------------------------------------------- -----------------------------------
US$24.74 300
------------------------------------------------------------------------------- -----------------------------------
US$24.75 802
------------------------------------------------------------------------------- -----------------------------------
US$24.80 400
------------------------------------------------------------------------------- -----------------------------------
US$24.79 31
------------------------------------------------------------------------------- -----------------------------------
US$25.08 1,748
------------------------------------------------------------------------------- -----------------------------------
US$25.07 300
------------------------------------------------------------------------------- -----------------------------------
US$25.06 52
------------------------------------------------------------------------------- -----------------------------------
US$25.09 703
------------------------------------------------------------------------------- -----------------------------------
d) Aggregated information Aggregated volume: 5,336 ADSs
- Aggregated volume Price information: US$24.92
- Price
----- ------------------------------------ -------------------------------------------------------------------------
e) Date of the transaction 2017-08-16 - acquisition of 2,533 ADSs
2017-08-17 - acquisition of 2,803 ADSs
----- ------------------------------------ -------------------------------------------------------------------------
f) Place of the transaction Nasdaq Stock Market
----- ------------------------------------ -------------------------------------------------------------------------
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited ("CK Hutchison") (SEHK: 0001). For more information, please visit: www.chi-med.com.
CONTACTS
Investor Enquiries Mark Lee, SVP Corporate Finance & Development +852 2121 8200 U.K. & International Media Enquiries Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk U.S. Based Media Enquiries Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com Investor Relations Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk Panmure Gordon (UK) Limited Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLIFVATAITLID
(END) Dow Jones Newswires
August 18, 2017 05:50 ET (09:50 GMT)
1 Year Hutchmed (china) Chart |
1 Month Hutchmed (china) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
